TAOKA CHEMICAL COMPANY, LIMITED
4113・Standard Market・Chemicals
Business
Taoka Chemical is a fine chemicals manufacturer founded in 1919. Building on its long-standing organic synthesis technology, the company operates three businesses: agrochemical and pharmaceutical intermediates, electronic materials, and resin raw materials (Fine Chemicals Business); adhesives and rubber chemicals (Functional Materials Business); and plasticizers, processed resins, and varnishes (Resin Additives Business). In addition to its domestic Yodogawa Plant and Harima Plant, the company has overseas operations in India and China, with major customers including large chemical and materials manufacturers such as Mitsubishi Gas Chemical, Sumitomo Chemical, and Sumitomo Electric Wintec. Of the company's consolidated net sales of ¥33,192 million, approximately 98% is accounted for by the Chemical Industry segment, with the remainder attributable to the Contract Chemical Analysis Business.
Business Model
The company's basic approach is multi-product, small-lot production at its own plants, securing sales by continuously supplying agrochemical intermediates, resin raw materials, plasticizers, and other products to major chemical manufacturers. The policy is to pass on raw material and fuel cost increases to selling prices in a timely manner, while improving fixed-cost absorption capacity by raising plant utilization rates through the early introduction of contract-manufactured products. Capital expenditures are funded through financial institution borrowings and internal funds, with growth investments carried out in parallel while maintaining stable dividends.
Company Strengths
Since its founding in 1919, the company began with dye manufacturing and has since expanded its business domains into agrochemical intermediates, electronic materials, plasticizers, adhesives, and rubber chemicals. With 65 R&D personnel and R&D expenses of ¥843 million, the company has product development capabilities backed by accumulated technology, as evidenced by its bio-based plasticizer "TBIO+" winning the 76th Industrial Technology Award.
Sales to Mitsubishi Gas Chemical amounted to ¥11,802 million (35.6% of sales), Sumitomo Chemical ¥3,572 million (10.8%), and Sumitomo Electric Wintec ¥3,274 million (9.9%), with the top three companies accounting for approximately 56% of sales. Continuous transactional relationships with major customers form a stable order base.
In addition to three domestic sites—the Yodogawa Plant and the Harima Plant (Harima area and Ehime area)—the company owns overseas subsidiaries in India and China. In March 2022, a new multi-purpose plant (N-2) was completed at the Harima Plant, expanding production capacity. In FY2026 (ending March 2026), the company carried out capital expenditures of ¥1,240 million, continuing equipment modernization such as the DCS version upgrade at the Harima Plant.
ENVALITH's Perspective
Performance Trend
Revenue bottomed out in FY2023 (ending March 2023) at ¥30,167 million and has since recovered, reaching ¥33,192 million in FY2026 (ending March 2026), up 10.9% year on year, marking three consecutive years of revenue growth. The main driver of this revenue growth was increased shipments of resin raw materials in the Fine Chemicals Business (segment revenue of ¥16,535 million, up 25.0% year on year). Operating profit continued to improve, reaching ¥2,046 million (up 8.4% year on year), but remained below the ¥2,708 million recorded in FY2022 (ending March 2022). As an external factor, active capital investment amid the global expansion in generative AI-related demand pushed up demand for resin raw materials. On the other hand, for FY2027 (ending March 2027), the company forecasts a sharp deterioration in earnings, with operating profit of ¥320 million (down 84.4% year on year), against a backdrop of declining resin raw material shipments, rising raw material prices, and turmoil in the Middle East situation, raising concerns about the sustainability of profits.
Growth Strategy
Pursuing improved ROIC and operating margin, and enhanced corporate value under the medium-term plan "TCG as one 2027"
To compensate for the decline in utilization rates caused by reduced shipments of resin raw materials, the company is promoting the early introduction of newly developed products and contract-manufactured products. Given the significant profit decline forecast for FY2027 (ending March 2027), an early launch of alternative products is key to profit recovery.
In FY2027 (ending March 2027), revenue growth is expected due to increased sales of pharmaceutical and agrochemical intermediates. In FY2026 (ending March 2026), while pharmaceutical and agrochemical intermediates decreased, resin raw materials served as the main driver; in the next fiscal year, agrochemical intermediates are expected to become the primary driver of revenue growth.
Amid expectations of significant increases in raw material prices and supply constraints, the company aims to support profit margins through prompt reflection of cost changes in selling prices. The ability to pass on cost increases to customers will be an important measure for defending profitability in FY2027 (ending March 2027).
A medium-term plan aiming to improve ROIC and operating margin across all businesses. Net sales of ¥33,192 million in FY2026 (ending March 2026) represent approximately 83% of the ¥40.0 billion target. Due to the significant profit decline forecast for FY2027 (ending March 2027), achieving the target in the final year of the plan is expected to be difficult.
Last updated: July 19, 2026